Evotec SE ADR (EVO) - Total Assets
Based on the latest financial reports, Evotec SE ADR (EVO) holds total assets worth $1.77 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EVO net assets for net asset value and shareholders' equity analysis.
Evotec SE ADR - Total Assets Trend (2001–2024)
This chart illustrates how Evotec SE ADR's total assets have evolved over time, based on quarterly financial data.
Evotec SE ADR - Asset Composition Analysis
Current Asset Composition (December 2024)
Evotec SE ADR's total assets of $1.77 Billion consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.0% |
| Accounts Receivable | $218.38 Million | 11.4% |
| Inventory | $31.12 Million | 1.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.44 Million | 1.4% |
| Goodwill | $282.85 Million | 14.8% |
Asset Composition Trend (2001–2024)
This chart illustrates how Evotec SE ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EVO stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evotec SE ADR's current assets represent 35.7% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 14.8% of total assets.
Evotec SE ADR Competitors by Total Assets
Key competitors of Evotec SE ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Evotec SE ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 2.09 | 3.16 |
| Quick Ratio | 2.03 | 1.99 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $418.65 Million | $406.78 Million | $551.07 Million |
Evotec SE ADR - Advanced Valuation Insights
This section examines the relationship between Evotec SE ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -16.8% |
| Total Assets | $1.91 Billion |
| Market Capitalization | $1.15 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Evotec SE ADR's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Evotec SE ADR's assets decreased by 16.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Evotec SE ADR (2001–2024)
The table below shows the annual total assets of Evotec SE ADR from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.91 Billion | -16.81% |
| 2023-12-31 | $2.30 Billion | +1.85% |
| 2022-12-31 | $2.26 Billion | +0.99% |
| 2021-12-31 | $2.24 Billion | +21.63% |
| 2020-12-31 | $1.84 Billion | +33.18% |
| 2019-12-31 | $1.38 Billion | +78.76% |
| 2018-12-31 | $771.88 Million | +15.68% |
| 2017-12-31 | $667.27 Million | +89.91% |
| 2016-12-31 | $351.37 Million | +21.77% |
| 2015-12-31 | $288.54 Million | +28.47% |
| 2014-12-31 | $224.60 Million | -1.22% |
| 2013-12-31 | $227.38 Million | +0.87% |
| 2012-12-31 | $225.43 Million | +3.31% |
| 2011-12-31 | $218.21 Million | +13.74% |
| 2010-12-31 | $191.86 Million | +30.87% |
| 2009-12-31 | $146.60 Million | -19.85% |
| 2008-12-31 | $182.90 Million | -12.02% |
| 2007-12-31 | $207.88 Million | +1.14% |
| 2006-12-31 | $205.53 Million | +10.43% |
| 2005-12-31 | $186.11 Million | +162.46% |
| 2004-12-31 | $70.91 Million | +69.94% |
| 2003-12-31 | $41.73 Million | +123.10% |
| 2002-12-31 | $18.70 Million | -48.34% |
| 2001-12-31 | $36.20 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more